2015
Erratum to Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: A randomised, double-blind, phase 3 trial. [Lancet Oncol (2015) 16: 385-394]
Publication
Publication
The Lancet Oncology , Volume 16 - Issue 9 p. e427
Schöffski P, Ray-Coquard IL, Cioffi A, et al, for the European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG). Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol 2011; 12: 1045–52—
In the Discussion of this Article, the second sentence of the fifth paragraph should read “The proportion of patients affected by grade 3–4 fatigue in this study (7%) is similar to that reported for trabectedin (7–8%) or gemcitabine with docetaxel (16%).”
This correction has been made to the online version as of Aug 31, 2015.
| Additional Metadata | |
|---|---|
| doi.org/10.1016/S1470-2045(15)00237-5, hdl.handle.net/1765/85471 | |
| The Lancet Oncology | |
| Organisation | Department of Pediatrics |
|
Kang, H. J., Loftus, S., Taylor, A., DiCristina, C., Green, S., & Zwaan, M. (2015). Erratum to Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: A randomised, double-blind, phase 3 trial. [Lancet Oncol (2015) 16: 385-394]. The Lancet Oncology, 16(9). doi:10.1016/S1470-2045(15)00237-5 |
|